Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • Local Institution - 129 Scottsdale, Arizona, United States
  • Local Institution - 116 Scottsdale, Arizona, United States
  • Local Institution - 115 San Francisco, California, United States
  • Local Institution - 106 Aurora, Colorado, United States
View all 54 locations
View Trial Details
Completed

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

NCT02278796

Conditions
Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, Histiocytic Disorders, Malignant, +13 more
Locations
  • Krankenhaus der Elisabethinen Linz Linz, Austria
  • Hanusch Krankenhaus Wien Vienna, Austria
  • Department for Medical Oncology University Hospital/Inselspital Bern, Switzerland
  • Universitätsspital Zürich Zurich, Switzerland
View Trial Details
Completed

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

NCT03013218

Conditions
Advanced Cancer, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • University of Colorado Denver Denver, Colorado, United States
  • Yale University New Haven, Connecticut, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

NCT06163040

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Chang Gung Memorial Hospital- Chiayi Chiayi City, Chiayi, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung City, Taiwan
  • National Taiwan University Hospital Taipei, Taiwan
  • China Medical University Hospital Taoyuan City, Taiwan
View Trial Details
Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

NCT03548207

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Cancer Center-Scottsdale Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Chicago Chicago, Illinois, United States
View all 21 locations
View Trial Details

Related conditions